Mr. Sebastien Plouffe reports

DEFENCE CLOSES SECOND TRANCHE OF FULLY SUBSCRIBED FINANCING TOTALING $4.2 MILLION

Defence Therapeutics Inc. has closed the second tranche of its previously announced non-brokered private placement of units of the company at a price of 60 cents per unit for aggregate gross proceeds of $3,915,000.

Each unit consists of one common share in the capital of the company and one common share purchase warrant. Each warrant is exercisable to acquire one additional share at an exercise price of 75 cents per share for a period of 24 months from the date of the closing.

In connection with the closing, the company paid cash finders' fees consisting of: (i) a cash fee equal to $217,680; and (ii) issued a total of 372,000 finders' warrants to certain qualified arm's-length finders. Each finder's warrant is exercisable into one share at an exercise price of 75 cents per share on or before the warrant expiry date. PowerOne Capital Markets Ltd. acted as a finder in connection with a portion of the offering.

The company intends to use the net proceeds of the offering to advance its preclinical and clinical programs, and for general working capital. All securities issued in connection with the offering are subject to a statutory hold period of four months plus a day from their date of issue in accordance with applicable securities legislation.

The company has granted 250,000 incentive stock options to two board members and 100,000 incentive stock option to a consultant, in accordance with the terms and conditions of Defence's omnibus incentive plan. The stock options granted are vested immediately and exercisable at a price of $1.02 per common share of the company, of which the directors' options are for a period of 10 years from the grant date and the consultant's options are for a period of three years.

About Defence Therapeutics Inc.

Defence Therapeutics is a publicly traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform in addition to novel immune-oncology vaccines. The core of Defence Therapeutics platform is the Accum technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.

We seek Safe Harbor.